Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

[Proces urządzenia, który nie jest zatwierdzony ani oczyszczony przez FDA USA]

10 listopada 2026 zaktualizowane przez: BioPoly LLC

The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group.

The primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by:

  • no secondary surgical intervention (SSI) and
  • an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points.

Researchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement).

Subjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.

Przegląd badań

Szczegółowy opis

The BioPoly® Partial Resurfacing Knee Implant is a surgical intervention when conservative therapies have been ineffective for focal cartilage lesions in the femoral condyles and is an early intervention prior to partial or total joint replacement. It is indicated for focal lesions with healthy surrounding and opposing cartilage. Specifically, the BioPoly® device is intended for the replacement of symptomatic abnormal or severely abnormal (ICRS Grade 2, 3 or 4) chondral or osteochondral focal lesions located in the femoral condyles or trochlear facets in patients between 30 and 65 years of age.

The RCT compares the primary endpoint, Composite Clinical Success criteria, for the investigational device, the BioPoly device, to that of the control group, which is the standard of care for these focal lesions either microfracture or debridement.

For those patients who meet eligibility criteria, randomization is 1:1. For the control group, there is a treatment algorithm to determine if microfracture or debridement that is based upon age of the subject, Kellgren-Lawrence score, and lesion size.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

152

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • California
      • Redwood City, California, Stany Zjednoczone, 94063
        • Rekrutacyjny
        • Stanford Medicine Dept of Orthopaedic Surgery
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Seth L Sherman, MD
    • Indiana
      • Fort Wayne, Indiana, Stany Zjednoczone, 46845
        • Rekrutacyjny
        • Dupont Hospital
        • Główny śledczy:
          • Ian Nelson, MD
      • Indianapolis, Indiana, Stany Zjednoczone, 46278
        • Wycofane
        • OrthoIndy
    • Kentucky
      • Louisville, Kentucky, Stany Zjednoczone, 40202
        • Rekrutacyjny
        • University of Louisville
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Jarod Richards, M.D.
        • Pod-śledczy:
          • David Caborn, M.D.
        • Pod-śledczy:
          • Stephanie Boden, M.D.
    • Minnesota
      • Rochester, Minnesota, Stany Zjednoczone, 55905
        • Rekrutacyjny
        • Mayo Clinic
        • Główny śledczy:
          • Daniel Saris, MD
        • Kontakt:
    • Missouri
      • Chesterfield, Missouri, Stany Zjednoczone, 63017-5701
        • Rekrutacyjny
        • Washington University Orthopedics
        • Kontakt:
        • Główny śledczy:
          • Matthew Matava, MD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

30 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Patient is between 30 and 65 years of age25.
  2. KOOS quality of life score ≤ 60.
  3. In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the Post-Operative rehabilitation and follow-up protocol.
  4. Patient has cartilage lesion that has failed non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) after at least 2 months of beginning the therapy or failed surgical conservative therapy (e.g. debridement/lavage, marrow stimulation, or alignment high tibial osteotomy) that was performed at least 12 months ago in the index knee and is a candidate for surgical intervention.
  5. Patient has cartilage lesion located in the femoral condyle or trochlear facet.
  6. Patient has lesion(s) classified as ICRS grade 2, 3 or 4.
  7. Patient's lesion size may not exceed 3.1 cm2 and must be circumscribed by a 1.5 cm or 2.0 cm diameter circle, or 1.5 cm (M-L) by 2.4 cm (A-P) oval of normal or nearly normal (ICRS grade 0 or 1) cartilage, with an overall depth less than 4mm from the articulating surface.
  8. Patient has subchondral bone quality that is non-osteoporotic and is sufficient to support the implant. The quality of bone will be assessed by the surgeon intraoperatively with a surgical instrument such as an awl.

Exclusion Criteria:

  1. Patient has body mass index (BMI) ≥ 35.

  2. Patient has autoimmune arthritis, as diagnosed by Investigator.

  3. Patient has advanced degenerative osteoarthritis in index knee (Kellgren-Lawrence Grade 4 and/or diagnosed intraoperatively).

  4. Contralateral knee is known to have symptomatic cartilage, meniscal, or ligamentous lesions, generalized osteoarthritis, or requires surgery.

  5. Patient has gout, by Investigator diagnosis or patient-reported history within last 12 months.

  6. Patient has a cartilage lesion that is being treated with a non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) and it has been < 2 months since beginning treatment or the patient's cartilage lesion has failed surgical therapy (e.g. debridement/lavage, marrow stimulation, alignment (high tibial osteotomy)) in the index knee and it has been < 12 months since the surgical treatment.

  7. Patient has a cartilage lesion that is being treated that has failed ACI, OATS or Allograft treatment.

  8. Patient has malalignment of the index knee (>5 degrees weight bearing varus or valgus).

  9. Patient has bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e. greater than ICRS Grade 2 on the opposing articular surface) in the index knee.

  10. Patient has uncorrected ligamentous instability (good joint stability in the index joint with a Grade 1 Lachman or less, no pivot shift for ACL insufficiency and no posterior translation of more than grade 1; no deficits in flexion or extension of > 10 degrees compared to contralateral knee) in the index knee.

  11. Patient has undergone a total meniscectomy of index knee.

  12. Patient has undergone patellofemoral arthroplasty of the index knee

  13. Patient currently reports or has a documented history of uncontrolled diabetes.

  14. Patient currently has any condition, therapy, or medication known to impair bone healing.

  15. Patient has had an active systemic infection or joint infection in index knee over the last 12 months.

  16. Patient has an allergy to titanium alloy (Ti-6Al-4V), ultrahigh molecular weight polyethylene (UHMWPE), or hyaluronan/ hyaluronic acid (HA).

  17. Patient is pregnant or is planning to become pregnant (for female patients only) at any point during the duration of the study.

  18. Patient has legal involvement or any other issue that would hinder completion of the two-year follow-up period.

  19. Patient is participating in other studies and/or receiving any other simultaneous therapy in index knee.

  20. Patient has an uncorrected tear of the meniscus of the index knee. (Partial meniscectomy that retains >50% of the meniscus is allowed prior to or concurrently with the cartilage treatment procedure. Meniscus suture repair is allowed prior to or concurrently with the cartilage treatment procedure if >50% of the functional meniscus remains.).

  21. Patient has an additional cartilage lesion(s) (ICRS Grade 3 or 4) in the index knee, located on the patella, trochlea, tibia, or non-weight bearing area of index condyle that requires treatment.

  22. More than one implant is required to accommodate defect in the index knee.

  23. Patient has inadequate bone stock (e.g., cysts, osteoporosis) underlying the lesion site as determined intra-operatively by the investigator

    1. As determined by the investigator through use of an awl or a similar instrument to determine if the bone quality is insufficient to support the BioPoly device.
    2. If the cause of inadequate bone stock is due to cysts or to the boney portion of an osteochondral lesion being excessive, then the investigator may opt to fix the implant with cement rather than exclude the patient for inadequate bone stock.
  24. Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA T-score < -2.5 or QCT T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Investigational

BioPoly Knee device

partial resurfacing knee replacement

Aktywny komparator: Control

Surgical Standard of Care Group: either Microfracture or debridement procedure

either microfracture or debridement

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Improvement in the Knee injury and Osteoarthritis Outcome Score (KOOS) to Assess Composite Clinical Success (CCS) effectiveness
Ramy czasowe: 24 months

An improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points. If this criteria is met, the subject will be considered as a success relative to the measure of the Clinical Composite Success for effectiveness.

24 months
Composite Clinical Success (CCS) Safety as Measured by No Secondary Surgical Intenvention
Ramy czasowe: 24 months

No secondary surgical intervention (SSI) by 24 months will be considered as a success for the subject relative to the Composite Clinical Success (CCS) for Safety.

24 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Effectiveness over 24 months as measured by the Knee injury and Osteoarthritis Outcome Score (KOOS)
Ramy czasowe: 24 months

KOOS individual component sub-scales (Pain, Symptoms, Activities of Daily Living, Sports/Recreation, Quality of Life) as measured by change from baseline at 6 weeks, 3, 6, 12, and 24 months. The minimum and maximum raw scores for each sub-scale is as follows: Pain = 0-36, Symptoms = 0-28, Activities of Daily Living = 0-38, Sports/Recreation = 20, Quality of Life = 0-16. The sub-scales will be reported on a normalized scale relative the maximum raw score for the particular sub-scale, thus, each sub-scale score will have a range of 0-100 with 100 being better. For instance, a subject's Quality of Life raw score of 12 would be normalized as 12/16 x 100 = 75 points. The reported number will be the difference between the normalized score at a particular timepoint minus the baseline normalized score.

24 months
Effectiveness pain reduction over 24 months
Ramy czasowe: 24 months

Variable Analog Scale (VAS) Pain score as measured by change from baseline at 6 weeks, 3, 6, 12, and 24 months. The VAS Pain score ranges from 0-100 where a lower number is a measure of less pain; so, lower VAS Pain scores are better.

24 months
Adverse Events Over 24 Months
Ramy czasowe: 24 months
  • Serious device-related adverse events through 24 months
  • Device-related adverse events through 24 months
  • Serious adverse events through 24 months
  • Unanticipated adverse device effects (UADE) through 24 months
24 months
Radiograph review to Assess Implant Stability Over 24 Months
Ramy czasowe: 24 months

Implant stability over time is assessed by monitoring implant migration/subsidence, implant loosening, and radiolucencies around the implant at 24 months.

24 months
Survival Over 24 Months
Ramy czasowe: 24 months

A survival analysis will be performed to determine the number of treated and control subjects that did not have a secondary surgical intervention to remove the implant or to perform another procedure to treat the same cartilage lesion.

24 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Herb Schwartz, Ph.D., BioPoly LLC

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

17 marca 2025

Zakończenie podstawowe (Szacowany)

1 grudnia 2028

Ukończenie studiów (Szacowany)

1 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

24 marca 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

3 kwietnia 2025

Pierwszy wysłany (Rzeczywisty)

8 kwietnia 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Sharing of any data will only be in the aggregate.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj